Cargando…

Quantifying the economic burden of unintended pregnancies due to drug–drug interactions with hormonal contraceptives from the United States payer perspective

Background: In the United States of America (USA), nearly 10 million women use oral contraceptives (OCs). Concomitant administration of certain medications can result in contraceptive failure, and consequently unintended pregnancies due to drug–drug interactions (DDIs). The objective of this analysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srinivasan, Meenakshi, White, Annesha, Lott, Jason, Williamson, Todd, Kong, Sheldon X, Plouffe, Leo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722710/ https://www.ncbi.nlm.nih.gov/pubmed/36523752 http://dx.doi.org/10.12688/gatesopenres.13430.1

Ejemplares similares

Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development
por: Srinivasan, Meenakshi, et al.
Publicado: (2020)

Development of a pharmacoeconomic registry: an example using hormonal contraceptives
por: White, Annesha, et al.
Publicado: (2021)

Establishing a Multidisciplinary Framework to Study Drug‐Drug Interactions of Hormonal Contraceptives: An Invitation to Collaborate
por: Lesko, Lawrence J., et al.
Publicado: (2018)

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
por: Sikirica, Mirko, et al.
Publicado: (2014)

Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs
por: Anderson, Seri, et al.
Publicado: (2021)

Are payers treating orphan drugs differently?
por: Cohen, Joshua P., et al.
Publicado: (2014)

Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market
por: Shih, Ya-Chen Tina, et al.
Publicado: (2021)

Economic Burden of Contraception Management in Spain
por: Parra Ribes, Inmaculada, et al.
Publicado: (2018)

Drug interactions between hormonal contraceptives and antiretrovirals
por: Nanda, Kavita, et al.
Publicado: (2017)

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
por: Cicin, Irfan, et al.
Publicado: (2021)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)

Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs
por: Chambers, James D., et al.
Publicado: (2016)

Unintended Pregnancies, Their Outcome and Prior Usage of Contraception in Georgia
por: JAPARIDZE, Tamar, et al.
Publicado: (2017)

Prevalence of Drug–Drug Interactions with Hormonal Contraceptives and Antiretrovirals in Women Living with HIV
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Unmet need for contraception and its association with unintended pregnancy in Bangladesh
por: Bishwajit, Ghose, et al.
Publicado: (2017)

Drug voyager: a computational platform for exploring unintended drug action
por: Oh, Min, et al.
Publicado: (2017)

Payer perceptions on the use of economic models in oncology decision making
por: Biskupiak, Joseph, et al.
Publicado: (2021)

Exploring the relationship between socioeconomic factors, method of contraception and unintended pregnancy
por: Metcalfe, Amy, et al.
Publicado: (2016)

Contraceptive Use and Unintended Pregnancies Among HIV-Infected Women in Mumbai
por: Joshi, Beena, et al.
Publicado: (2015)

Prevention of unintended pregnancy and use of contraception—important factors for preconception care
por: Kallner, Helena Kopp, et al.
Publicado: (2016)

Unintended Effects of Cardiovascular Drugs on the Pathogenesis of Alzheimer’s Disease
por: Wang, Jun, et al.
Publicado: (2013)

Incremental Health Care Resource Utilization and Economic Burden of Venous Thromboembolism Recurrence from a U.S. Payer Perspective
por: Lin, J., et al.
Publicado: (2014)

Potential risk of drug–drug interactions with hormonal contraceptives and antiretrovirals: prevalence in women living with HIV
por: Murray, Milena M, et al.
Publicado: (2020)

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
por: Solà-Morales, Oriol, et al.
Publicado: (2019)

Clinical and economic burden of adverse drug reactions
por: Sultana, Janet, et al.
Publicado: (2013)

Quantifying the global burden of mental disorders and their economic value
por: Arias, Daniel, et al.
Publicado: (2022)

The Payer's Dilemma: Recognizing the Uncertainty of Clinical and Economic Evidence at Product Launch
por: Watkins, John B., et al.
Publicado: (2009)

Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception
por: Henry, Nathaniel, et al.
Publicado: (2015)

Contraceptive use and unintended pregnancy among young women and men in Accra, Ghana
por: Grindlay, Kate, et al.
Publicado: (2018)

Unintended pregnancy and subsequent postpartum long-acting reversible contraceptive use in Zimbabwe
por: Nance, Nerissa, et al.
Publicado: (2018)

Contraceptive use following unintended pregnancy among Ugandan women living with HIV
por: Jarolimova, Jana, et al.
Publicado: (2018)

Access Denied? The Unintended Consequences of Pending Drug Pricing Rules
por: Kaplan, Alan, et al.
Publicado: (2022)

Mysteriously Puffy Extremities: An Unintended Consequence of Intravenous Drug Abuse
por: Janardan, Abhishek, et al.
Publicado: (2022)

Considerations for payers in managing hormone receptor-positive advanced breast cancer
por: Chitre, Mona, et al.
Publicado: (2014)

A Pharmacoepidemiologic Approach to Evaluate Real-world Effectiveness of Hormonal Contraceptives in the Presence of Drug–drug Interactions
por: Sarayani, Amir, et al.
Publicado: (2020)

Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system
por: Sunaga, Tomiko, et al.
Publicado: (2021)

Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database
por: Pandya, Bhavik J., et al.
Publicado: (2020)

Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018
por: Peet, Evan D., et al.
Publicado: (2022)

Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies
por: Chambers, James D., et al.
Publicado: (2018)

Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers
por: Lopata, Erin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f9el3g71u8sr3d6n4vjdujqvim